Format

Send to

Choose Destination
Viruses. 2017 Jul 4;9(7). pii: E172. doi: 10.3390/v9070172.

Hepatitis Delta Virus: Replication Strategy and Upcoming Therapeutic Options for a Neglected Human Pathogen.

Author information

1
Department of Infectious Diseases, Molecular Virology, Heidelberg University, Im Neuenheimer Feld 345, 69120 Heidelberg, Germany. Florian.Lempp@med.uni-heidelberg.de.
2
German Centre for Infection Research (DZIF), Partner Site Heidelberg, 69120 Heidelberg, Germany. Florian.Lempp@med.uni-heidelberg.de.
3
Department of Infectious Diseases, Molecular Virology, Heidelberg University, Im Neuenheimer Feld 345, 69120 Heidelberg, Germany. Stephan.Urban@med.uni-heidelberg.de.
4
German Centre for Infection Research (DZIF), Partner Site Heidelberg, 69120 Heidelberg, Germany. Stephan.Urban@med.uni-heidelberg.de.

Abstract

The human Hepatitis Delta Virus (HDV) is unique among all viral pathogens. Encoding only one protein (Hepatitis Delta Antigen; HDAg) within its viroid-like self-complementary RNA, HDV constitutes the smallest known virus in the animal kingdom. To disseminate in its host, HDV depends on a helper virus, the human Hepatitis B virus (HBV), which provides the envelope proteins required for HDV assembly. HDV affects an estimated 15-20 million out of the 240 million chronic HBV-carriers and disperses unequally in disparate geographical regions of the world. The disease it causes (chronic Hepatitis D) presents as the most severe form of viral hepatitis, leading to accelerated progression of liver dysfunction including cirrhosis and hepatocellular carcinoma and a high mortality rate. The lack of approved drugs interfering with specific steps of HDV replication poses a high burden for gaining insights into the molecular biology of the virus and, consequently, the development of specific novel medications that resiliently control HDV replication or, in the best case, functionally cure HDV infection or HBV/HDV co-infection. This review summarizes our current knowledge of HBV molecular biology, presents an update on novel cell culture and animal models to study the virus and provides updates on the clinical development of the three developmental drugs Lonafarnib, REP2139-Ca and Myrcludex B.

KEYWORDS:

Hepatitis D virus; Myrcludex B; REP2139-Ca; lonafarnib; viroid

PMID:
28677645
PMCID:
PMC5537664
DOI:
10.3390/v9070172
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center